Objective

Cancer immunotherapy utilises the components of the immune system to treat cancer patients. These therapies are designed to work with a patient’s immune system to increase native anti-tumour responses. One type of immunotherapy relies on antibodies to bind to and inhibit the function of proteins expressed by the cancer cell. To investigate and develop immunotherapies in mice, syngeneic models must be used instead of xenograft models that lack a native immune system and often use human cell lines. Syngeneic mouse models, using tumour grafts derived from immortalised mouse cancer cell lines, allow the study of cancer therapies in the presence of an intact immune system. However, working in mouse systems can often require the development of separate mouse reagents, if the therapeutic agent of interest does not cross-react with mouse. The AlphaLISA® mouse PD-1/PD-L1 binding kit and AlphaLISA human PD-1/PD-L1 binding kit enable basic researchers and drug discovery researchers to develop and characterise anti-mouse or anti-human PD-1 and PD-L1 reagents for in-vitro and in-vivo studies, to test putative binding ligands (such as PD-L2) or to characterise protein sub-regions for their ability to block the PD-1/PD-L1 binding interaction.